Caladrius Biosciences Inc., a prominent American biopharmaceutical company, has been making waves in the cell therapy industry due to its subsidiary PCT's expertise in development and manufacturing of cell therapies. PCT has emerged as a key partner for companies in the cell therapy domain, supporting several clinical trials and working on the production of tailored cell therapy treatments. With a strong track record of success and adoption across the sector, the company stands as a solid bet for investors looking to bank on the future of cell therapy.